


In the claims:

Amend the claims as indicated below and cancel 8.


(1)

1. (Amended) An antibiotic, caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E and ~~or~~ caprazamycin F, which is a compound represented by the following ~~general~~ formula (I)




wherein, R is tridecyl group for caprazamycin A; 11-methyl-dodecyl group for caprazamycin B; dodecyl group for caprazamycin C; undecyl group for caprazamycin E; and 9-methyl-decyl group for caprazamycin F, and ~~or~~ a pharmaceutically acceptable salts ~~salt~~ thereof.

2. ~~The An~~ antibiotic of ~~as claimed in~~ Claim 1[[,]] which is caprazamycin A represented by the following formula (Ia)




that is, the compound of ~~general~~ formula (I) shown in Claim 1 where R is tridecyl group - $(\text{CH}_2)_{12}-\text{CH}_3$.


3. (Amended) ~~The An~~ antibiotic of ~~as claimed in~~ Claim 1[[,]] which is caprazamycin B represented by the following formula (Ib)



where R is 11-methyl-dodecyl group




formula (Ic)




where R is dodecyl group $-(CH_2)_{11}-CH_3$.

5. (Amended) The ~~An~~ antibiotic of ~~as claimed in~~ Claim 1[[,]] which is caprazamycin E represented by the following formula (Ie)




that is, the compound of general formula (I) shown in Claim 1 where R is undecyl group $-(\text{CH}_2)_{10}-\text{CH}_3$.

6. (Amended) The ~~An~~ antibiotic of ~~as claimed in~~ Claim 1[[,]] which is caprazamycin F represented by the following formula (If)



that is, the compound of ~~general~~ formula (I) shown in Claim 1 where R is 9-methyl-decyl group



7. (Amended) A process for the production of an antibiotic[[,]] ~~caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E and/or caprazamycin F~~ represented by the ~~general~~ formula (I) ~~given~~ in Claim 1, ~~characterized in that~~ the process comprising ~~comprises~~ culturing the a microbial strain Streptomyces sp. MK730-62F2 ~~which belongs to the genus Streptomyces~~ and which is capable of producing at least one of caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E

and caprazamycin F, and recovering at least one of caprazamycin ~~caprazamycins~~ A, B, C, E and F from the resulting culture.

8. (Canceled)

9. (Amended) A pharmaceutical composition having ~~comprising~~ as an active ingredient at least one of caprazamycin ~~caprazamycins~~ A, B, C, E and F having the ~~general~~ formula (I) given in Claim 1, or a salt thereof, in admixture with a pharmaceutically acceptable carrier or carriers.

10. (Amended) The A composition of claim 9 which is an antibacterial. ~~as claimed in Claim 9, which is an antibacterial composition.~~

11. (Amended) A biologically pure culture of ~~As a novel microorganism,~~ Streptomyces sp. MK730-62F2 which has a characteristic nature that it is capable of producing caprazamycin ~~caprazamycins~~ A, B, C, E and F of ~~having~~ the ~~general~~ formula (I) given in Claim 1, ~~and which has been deposited in the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, under the deposit number of "FERM BP-7218".~~

Remarks

This Amendment is submitted in response to the office action of September 23, 2003 in which an objection was made to the specification and claims were rejected under §112, 103 and 102(b).

The specification has been amended to include a reference to the PCT priority application. We note that this is an unusual requirement in our experience, since this is an